Table 1 Characteristics of 31 patients who received allo-HSCT after 8-Gy TBI/FLU/CY conditioning regimen
Characteristics | Value |
|---|---|
Sex, no. Male | 16 |
Female | 15 |
Median age at transplantation, years (range) | 8.0 (0.8–18.7) |
Median time from diagnosis to transplantation, months (range) | 9 (2–92) |
Diagnoses, no. of recipients | |
ALL | 11 |
CR1 (MRD+) | 4 (0) |
CR2 (MRD+) | 7 (0) |
B-lineage (MLL rearrangement) | 9 (2) |
T-lineage | 2 |
AML | 13 |
CR1 | 3 |
CR2 | 4 |
Refractory disease | 6 |
M2 [t(8;21)] | 5 (4) |
M3 [t(15;17] | 1 (1) |
M5 (MLL rearrangement) | 1 (1) |
M6 | 1 |
M7 (monosomy 7/trisomy 8) | 5 (2/3) |
MDS | 4 |
CR1 | 1 |
Untreated primary disease | 3 |
RAEB-2 (monosomy 7) | 2 (1) |
RCMD (monosomy 7) | 2 (2) |
JMML | 1 |
Untreated primary disease | 1 |
ALAL | 2 |
CR1 (MRD+) | 1 (0) |
CR2 (MRD+) | 1 (0) |
Cytogenetic abnormalities | |
MLL rearragement | 3 |
monosomy 7 | 5 |
trisomy 8 | 3 |
t(8;21) | 4 |
t(15;17) | 1 |
normal karyotype | 10 |
others | 5 |
Central nervous system disease | 2 |
Stem cell source (HLA-matching: A, B, C, DRB1) | |
Related BM, 8/8 | 6 |
Related BM, 7/8 | 3 |
Related BM, 6/8 | 2 |
Related BM, 5/8 | 1 |
Related BM, 4/8 | 3 |
Unrelated BM, 8/8 | 4 |
Unrelated BM, 7/8 | 2 |
Unrelated CB, 7/8 | 4 |
Unrelated CB, 6/8 | 5 |
Unrelated CB, 5/8 | 1 |
Infused cell dose | |
BM TNC, ×108 | 4.30 (1.9–15.6) |
BM CD34, ×106 | 3.99 (1.8–14.0) |
CB TNC, ×108 | 0.65 (0.23–1.26) |
CB CD34, ×106 | 0.14 (0.07–0.27) |
